Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations.mAbs
   Pooled it
2. Molecular Profiling and Targeted Therapeutic Strategies in Breast Cancer: Clinical Integration of HER2, CDK4/6, and PI3K Inhibition with Trastuzumab, Abemaciclib and Alpelisib.Journal of clinical medicine · 2026
   Review
3. Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice.Medicina (Kaunas, Lithuania) · 2024
   Review
4. Advancing perspectives on the off-label use of anticancer drugs: an updated classification and exploration of categories.Frontiers in pharmacology · 2024
   Review
5. Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer.International journal of breast cancer · 2024
   Article
6. Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021.Biomedicines · 2022
   Review
7. Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer - A retrospective cohort study.Breast (Edinburgh, Scotland) · 2021
   Article
8. Opportunities in an Evolving Pharmaceutical Development Landscape: Product Differentiation of Biopharmaceutical Drug Products.Pharmaceutical research · 2021
   Review
9. Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics.mAbs
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as